MARKET

LXRX

LXRX

Lexicon PHARM
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.74
-0.05
-0.66%
After Hours: 6.76 +0.03 +0.37% 17:43 03/08 EST
OPEN
6.80
PREV CLOSE
6.78
HIGH
7.01
LOW
6.61
VOLUME
940.99K
TURNOVER
--
52 WEEK HIGH
9.65
52 WEEK LOW
1.030
MARKET CAP
952.98M
P/E (TTM)
-6.4216
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings
Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA...
Benzinga · 2d ago
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast on March 10, 2021
THE WOODLANDS, Texas, March 04, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2020 financial results on Wednesday, March 10, 2021 after the markets close. Management will conduct a conf...
GlobeNewswire · 4d ago
Will Lexicon Pharmaceuticals (LXRX) Report Negative Q4 Earnings? What You Should Know
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 4d ago
Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails
Zacks.com · 5d ago
Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails
Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.
Zacks · 5d ago
Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus
Zacks.com · 6d ago
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates
Zacks.com · 6d ago
Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA
Zacks.com · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LXRX. Analyze the recent business situations of Lexicon PHARM through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LXRX stock price target is 8.00 with a high estimate of 13.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 202
Institutional Holdings: 123.22M
% Owned: 87.08%
Shares Outstanding: 141.50M
TypeInstitutionsShares
Increased
25
16.47M
New
44
9.58M
Decreased
31
8.27M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
Raymond Debbane
President/Chief Executive Officer/Director
Lonnel Coats
Chief Financial Officer/Executive Vice President
Jeffrey Wade
Executive Vice President
Alan Main
Executive Vice President
Praveen Tyle
Vice President - Finance
James Tessmer
Vice President/General Counsel
Brian Crum
Independent Director
Philippe Amouyal
Independent Director
Samuel Barker
Independent Director
Robert Lefkowitz
Independent Director
Alan Nies
Independent Director
Frank Palantoni
Independent Director
Christopher Sobecki
Independent Director
Judith Swain
No Data
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatments for human disease. The Company's drug programs include Sotagliflozin and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development. The Company’s LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company intends to initiate a Phase IIa clinical trial evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic (DPN) pain. Its Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease.

Webull offers kinds of Lexicon Pharmaceuticals, Inc. stock information, including NASDAQ:LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.